Skip to main content


A new age of personalized cancer care begun with the introduction of the “Liquid Biopsy” concept. Novel blood test detect cancer cells, tumor-associated cells, and immune cells in the circulation and provide a non-invasive real-time picture of a patient’s malignant disease. The tests enable possible post-therapeutic surveillance of recurrence.

Blood-based biopsy diagnostics is a mix of high-tech technology and cutting edge medical procedures, and offers new ways for selection of the right drug for the right patient at the right time – all through a simple blood draw.

  • Cytokeratin 19 (CK-19) is a general marker of epithelial cells that is strongly expressed in epithelial but not in mesenchymal cells. Increased expression is seen during epithelial embryogenesis, tissue regeneration, tissue repair, tissue development, and carcinogenesis. CK-19 has been extensively studied as a potential marker for the detection of circulating tumor cells (CTC) in a variety of epithelial cancers. It is a cytoskeletal component present in normal and cancerous epithelial cells. It is expressed in 90% of invasive breast cancer tissue and thus, has been extensively used for the detection of breast cancer cells in mesenchymal tissues. It is probably the most sensitive and reliable tumor marker for the detection of CTC in patients with breast cancer.
    The list of innovative products comprises RT-qPCR-based tests for the quantification of CK-19 mRNA in RNA samples.

    Product Unit Size REF IFU Brochure Note
    CK-19 Kit 24 tests OL1011024 not for in vitro diagnostic use
    CK-19 Kit LC 24 tests OL1010024 not for in vitro diagnostic use
    CK-19 Kit LC 48 tests OL1010048 not for in vitro diagnostic use
    CK-19 Kit LC 96 tests OL1010096 not for in vitro diagnostic use
    CK-19 Kit CE-IVD 24 tests OL1010124 – coming soon
    CC CK-19 610-670 Kit 1 run OL0010006 not for in vitro diagnostic use
    CC CK-19 610-670 Kit CE-IVD 1 run OL0010106 – coming soon

  • Detecting Rare Cells in blood and other body fluids can be a real challenge. OncoLab provides research tools that make hunting for rare cells, such as circulating tumor cells (CTC), circulating endothelial cells (CEC), or circulating stromal cells (CSC) a simple diagnostic test.
    OncoLab’s Circulating Rare Cell (CRC) tests are based on fluorescent immunostaining of rare cells after enrichment from blood samples. State-of-the-art biomarkers coupled with enhanced scanning optical systems powered by artificial intelligence enable convenient and efficient research of CRC.
    The list of products comprises special blood collection tubes, tools and reagents for cell purification, proprietary immunofluorescent cocktails for staining (IF), tools and general use reagents for preparing cytology slides, microscope imaging, and image analysis.

    Product Unit Size REF IFU Brochure Note
    nPACTM CTC IF Kit 12 rxn OL5010012   not for in vitro diagnostic use
    nPACTM CSC IF Kit 12 rxn OL5080012   not for in vitro diagnostic use
    nPACTM CSC/CEC IF Kit 12 rxn OL5070012   not for in vitro diagnostic use
    Blood Collection Kit CE-IVD 12 samples OL6010112    
    CRC IF Materials Kit 12 samples OL5090012     not for in vitro diagnostic use
    nCyte DxTM Advanced Optical Scanner
    incl. nAble® Software
    1 instrument OL90100   not for in vitro diagnostic use

  • Several tests for PCR-based detection and molecular characterization of circulating tumor cells (CTC) are under development.

    The list of future products comprises multi-marker tests for breast cancer, lung cancer, ovarian cancer, cervical cancer, endometrial cancer, and neuroendocrine tumors. Tools and reagents for collecting and stabilizing patients‘ blood samples, enrichment of circulating rare cells (CRC), or depletion of unwanted cells are in the pipeline as well.

    Methods and tests for the detection and quantification of protein aggregates are another focus of research and product development at OncoLab. Inactivation of protein function by aggregation plays an important role in cancer and several other diseases, like neurodegenerative disorders, amyloid transthyretin cardiomyopathy and type-2 diabetes. Products for the detection and quantification of disease associated aggregated proteins in tissues, cells and microvesicles are under development.

    The diagnostic impact of cell-free circulating RNA (cfRNA) levels in various bodily fluids and preparation of exosomes is another research topic.

    Proprietary mRNAs and miRNAs are investigated as possible diagnostic targets for gynecologic malignancies and other cancerous diseases.